NovMetaPharma Co Ltd
229500
Company Profile
Business description
NovMetaPharma Co Ltd researches and develops new medicines and health supplements for metabolic diseases. The company also sells C01 and CZ raw materials to partners conducting joint research and development, and also sells health functional foods.
Contact
727 Eonju-ro
13th floor, Nonhyeon-dong, Trees Building
Gangnam-gu
Seoul
KORT: +82 25381893
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
20
Stocks News & Analysis
stocks
After earnings, is Microsoft a buy, a sell, or fairly valued?
With third-quarter results surpassing even high-end expectations, here’s what we think of Microsoft stock.
stocks
Albemarle earnings: Shares rally on strong profit growth well above consensus estimates
Albemarle should see sequential profit growth in the second quarter and maintain higher profits through the year.
stocks
Ahead of IPOs, AI giants keep making circular deals. Here’s why that’s a risk - Clone
With OpenAI reportedly missing revenue targets, the imbalanced risks of circular deals become clearer.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,986.90 | 25.20 | -0.28% |
| CAC 40 | 8,202.08 | 97.34 | -1.17% |
| DAX 40 | 24,663.61 | 255.08 | -1.02% |
| Dow JONES (US) | 49,596.97 | 313.62 | -0.63% |
| FTSE 100 | 10,276.95 | 161.71 | -1.55% |
| HKSE | 26,364.35 | 261.93 | -0.98% |
| NASDAQ | 25,806.20 | 32.75 | -0.13% |
| Nikkei 225 | 62,480.59 | 353.25 | -0.56% |
| NZX 50 Index | 13,207.03 | 63.58 | -0.48% |
| S&P 500 | 7,337.11 | 28.01 | -0.38% |
| S&P/ASX 200 | 8,751.90 | 28.90 | -0.33% |
| SSE Composite Index | 4,169.08 | 11.02 | -0.26% |